Topical mupirocin for eradication of MRSA colonization with mupirocin-resistant strains.
Topical mupirocin was able to interrupt colonization of 52% and 68% of methicillin-resistant Staphylococcus aureus (MRSA)-colonized patients carrying mupirocin-resistant and -sensitive strains, respectively, including 44.4% and 85.7% of those colonized only in the nares. Although a trend to decreased effectiveness was seen for clearing mupirocin-resistant MRSA, this agent can decolonize many patients with resistant strains.
Semret
M
M
Department of Microbiology, SMBD-Jewish General Hospital, Montreal, Quebec, Canada.
Miller
M A
MA
D000287:Administration, Topical; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D006764:Hospitals, Community; D006801:Humans; D017053:Infection Control / Q000379:methods; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D016712:Mupirocin / Q000008:administration & dosage* / Q000494:pharmacology; D011792:Quebec; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D016712:Mupirocin